MDxHealth, Inc. Shareholder Transparency Notification
Published: May 16, 2017
Shareholdings after actively crossing the transparency threshold:
Capfi Delen Asset Management informed MDxHealth on May 11, 2017 that, as of May 8, 2017, its participation in MDxHealth increased above the threshold of 3% of the outstanding shares. Capfi Delen Asset Management now owns 1,522,000 shares, i.e. 3.05 %, of the outstanding shares of MDxHealth. Capfi Delen Asset Management is a Belgian Management Company of UCITS. For further information, reference is made to the information published on MDxHealth's website (http://www.mdxhealth.com/investors/shareholder-information).
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.
For more information:
Jean-Marc Roelandt, Chief Financial Officer
+32 (0) 4 364 20 70
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.Attachments: